MassDevice.com’s new Predictive Intelligence service aims to better anticipate and plan for major market events.
The idea is to harness the wisdom of crowds by polling our audience of medical device experts to assess the likelihood of certain outcomes in medtech – the odds that a device will win approval, the chances of a merger happening, the prospects for a new medical technology.
Our 1st Predictive Intelligence survey concerns the upcoming FDA panel meeting on Boston Scientific‘s (NYSE:BSX) Watchman anti-stroke heart implant.
The Watchman heart implant is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there.
The FDA committee plans to convene Dec. 11 to discuss whether the Watchman device is safe and effective enough to recommend that the watchdog agency approve the device. Although the FDA is not bound by the recommendations of its advisory panels, it often follows their lead.
Take the survey and gain exclusive access to our Predictive Intelligence results.